4 References
  1. Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the ”cisplatin era”. Gynecol Oncol. 2015 Feb;136(2):224-9. doi: 10.1016/j.ygyno.2014.12.010.
  2. Chu R, Liu P, Chen J, Cheng X, Li K, Che Y, Wang J, Li L, Zhang X, Yao S, Song L, Zhao Y, Huang C, Xue Y, Pan X, Li J, Chen Z, Jiang J, Kong B, Song K. Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study. J Gynecol Oncol. 2023 Mar;34(2):e12. doi: 10.3802/jgo.2023.34.e12.
  3. Xu T, Sun F, Li Y. Long-Term Outcomes and Factors Related to the Prognosis of Pure Ovarian Dysgerminoma: A Retrospective Study of 107 Cases. Gynecol Obstet Invest. 2021;86(6):494-501. doi: 10.1159/000519515.
  4. Ayhan A, Tunç M, Akıllı H, Haberal N, Haberal A. Fertility-sparing approach to malignant ovarian germ cell tumors - Oncologic and obstetric outocome: A retrospective study. Int J Gynaecol Obstet. 2023 Sep 22. doi: 10.1002/ijgo.15141.
  5. Goyal LD, Kaur B, Goyal G, Rajora P. Unusual Cases of Pure Malignant Germ Cell Tumors of the Ovary: A Case Series on 10 Years Experience at a Tertiary Care Center. J Reprod Infertil. 2021 Oct-Dec;22(4):267-273. doi: 10.18502/jri.v22i4.7652.
  6. Kilic C, Cakir C, Yuksel D, Kilic F, Kayikcioglu F, Koc S, Korkmaz V, Kimyon Comert G, Turkmen O, Boran N, Turan T. Ovarian Dysgerminoma: A Tertiary Center Experience. J Adolesc Young Adult Oncol. 2021 Jun;10(3):303-308. doi: 10.1089/jayao.2020.0087.
  7. Sağnıç S, Karadağ C, Tuncer HA, Doğan S, Şimşek T. Reproductive and oncologic outcomes in women with non-epithelial ovarian cancer: Single center experience over 25 years. Turk J Obstet Gynecol. 2023 Jun 1;20(2):97-104. doi: 10.4274/tjod.galenos.2023.98036.
  8. Liu Q, Ding X, Yang J, Cao D, Shen K, Lang J, Zhang G, Xin X, Xie X, Wu Y. The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2013 Dec;131(3):551-4. doi: 10.1016/j.ygyno.2013.08.016.
  9. Maidarti M, Garinasih PD, Anggraeni TD. Conservative surgical staging as a means to preserve fertility in patients with dysgerminoma: a case report. Ann Med Surg (Lond). 2023 Feb 13;85(3):427-430. doi: 10.1097/MS9.0000000000000146.
  10. Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K. Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecol Oncol. 2017 Dec;147(3):493-496. doi: 10.1016/j.ygyno.2017.10.010.
  11. Ghalleb M, Bouzaiene H, Slim S, Hadiji A, Hechiche M, Ben Hassouna J, Rahal K. Fertility-sparing surgery in advanced stage malignant ovarian germ cell tumor: a case report. J Med Case Rep. 2017 Dec 17;11(1):350. doi: 10.1186/s13256-017-1516-8.
  12. Zamani N, Rezaei Poor M, Ghasemian Dizajmehr S, Alizadeh S, Modares Gilani M. Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences. BMC Womens Health. 2021 Aug 4;21(1):282. doi: 10.1186/s12905-021-01437-8.
  13. Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Utsumi F, Niimi K, Suzuki S, Kikkawa F. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol. 2018 Oct;219(4):385.e1-385.e7. doi: 10.1016/j.ajog.2018.07.021.
  14. A L Husaini H, Soudy H, El Din Darwish A, Ahmed M, Eltigani A, A L Mubarak M, Sabaa AA, Edesa W, A L-Tweigeri T, Al-Badawi IA. Pure dysgerminoma of the ovary: a single institutional experience of 65 patients. Med Oncol. 2012 Dec;29(4):2944-8. doi: 10.1007/s12032-012-0194-z.
  15. Rungoutok M, Suprasert P. Oncology and reproductive outcomes over 16 years of malignant ovarian germ cell tumors treated by fertility sparing surgery. World J Clin Oncol. 2022 Oct 24;13(10):802-812. doi: 10.5306/wjco.v13.i10.802.
  16. Akasaka M, Hirai T, Yoshida K, Kondo E, Ikeda T, Iwamoto T. Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy: a case series study. J Pharm Health Care Sci. 2022 Nov 17;8(1):33. doi: 10.1186/s40780-022-00265-8.
  17. Turkmen O, Karalok A, Basaran D, Kimyon GC, Tasci T, Ureyen I, Tulunay G, Turan T. Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. J Adolesc Young Adult Oncol. 2017 Jun;6(2):270-276. doi: 10.1089/jayao.2016.0086.